Hci Group Inc
Change company Symbol lookup
Select an option...
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
VLY Valley National Bancorp
Go

Financials : Insurance | Small Cap Blend
Company profile

HCI Group, Inc. (HCI) is an insurance holding company. The Company operates through four operating divisions: property and casualty insurance, reinsurance, investment real estate and information technology. Its operations include Insurance Operations and Other Operations. Its Insurance Operations include property and casualty insurance, and reinsurance. The Company, through its subsidiary, Homeowners Choice Property & Casualty Insurance Company, Inc. (HCPCI), provides property and casualty insurance to homeowners, condominium owners and tenants on properties located in Florida. HCPCI also offers flood-endorsed and wind-only policies to new and pre-existing Florida customers. Its Other Operations include information technology (IT) and real estate. The Company's real estate operations consist of multiple properties it owns and operates.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$50.50
Day's Change
1.67 (3.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
50.65
Day's Low
48.59
Volume
(Average)
Volume:
34,866

10-day average volume:
34,098
34,866

FDA to require 2-month follow-up period for COVID-19 vaccines before authorization

1:20 pm ET October 6, 2020 (MarketWatch)
Print

Pharmaceutical companies developing COVID-19 vaccines should wait two months after late-stage studies conclude to submit an application for an emergency use authorization to the Food and Drug Administration, the regulator said Tuesday. In a guidance document (https://www.fda.gov/media/142723/download%7CNEW) released in advance of a planned Oct. 22 meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA said an application should include "data from Phase 3 studies that includes a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine's benefit-risk profile." It is also asking drug makers to wait until there are at least five cases of severe COVID-19 reported among the group of people who received the placebo. The New York Times this week had reported that the Trump administration is trying to block the two-month review (https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html%7CNEW) in order to speed up the authorization and distribution of coronavirus vaccines. A separate report in Politico this week said that White House officials had told Trump that the drug industry is resistant to the guidelines. There are four COVID-19 vaccine candidates in late-stage clinical trials (http://www.marketwatch.com/story/there-are-four-coronavirus-vaccines-in-late-stage-studies-heres-how-they-differ-2020-09-25%7CNEW) in the U.S., developed by AstraZeneca (AZN.LN) and the University of Oxford, BioNTech (BNTX) and Pfizer Inc. (PFE), Johnson & Johnson (JNJ), and Moderna Inc. (MRNA). None of these companies have released Phase 2 or Phase 3 clinical data at this time. Pfizer CEO Albert Bourla on Tuesday tweeted (https://twitter.com/AlbertBourla/status/1313504784134090754%7CNEW) that "Pfizer has never discussed [the FDA's COVID-19] vaccine guidelines with the White House and will never do so as it could undermine the agency's independence."

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 06, 2020 13:20 ET (17:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.